Basilea Pharmaceutica AG is a Swiss commercial-stage biopharmaceutical company focused on developing and commercializing drugs for severe bacterial and fungal infections. Headquartered in Allschwil, Switzerland, the company was spun off from F. Hoffmann-La Roche in 2000. Basilea's core business revolves around its two marketed hospital brands: Cresemba (isavuconazole), an intravenous and oral treatment for invasive fungal infections, and Zevtera (ceftobiprole), an advanced-generation cephalosporin antibiotic for severe bacterial infections. The company operates a partnership-driven commercial model, out-licensing its products to major pharmaceutical companies like Pfizer and Astellas for global distribution across the United States, Europe, and Asia. In addition to its commercialized products, Basilea maintains a robust clinical pipeline of novel antibacterial and antifungal candidates targeting critical priority pathogens. Following a strategic shift in 2022, the company completely withdrew from oncology research to focus exclusively on its anti-infective portfolio.
